PERTH, Australia – A new class of synthetic antibiotics with broad-spectrum activity is being developed by Sydney-based Recce Pharmaceuticals Ltd. that could solve the problem of antibiotic resistance.
PERTH, Australia – Sydney-based Kazia Therapeutics Ltd. has begun a U.S. phase II trial in glioblastoma with lead candidate GDC-0084, in-licensed from Roche Holding AG unit Genentech.
PERTH, Australia – A new class of synthetic antibiotics with broad-spectrum activity is being developed by Sydney-based Recce Pharmaceuticals Ltd. that could solve the problem of antibiotic resistance.
PERTH, Australia – A Senate inquiry on transvaginal mesh products is calling for patient registries for high-risk implantable devices, tighter postmarketing requirements and mandatory adverse event reporting requirements.
PERTH, Australia – Sydney-based Kazia Therapeutics Ltd. has begun a U.S. phase II trial in glioblastoma with lead candidate GDC-0084, in-licensed from Roche Holding AG unit Genentech.
PERTH, Australia – Pharmaceutical companies wanting to submit new drug applications in Australia now have additional pathways thanks to new drug legislation aimed at speeding access to therapies.
PERTH, Australia – Pharmaceutical companies wanting to submit new drug applications in Australia now have additional pathways thanks to new drug legislation aimed at speeding access to therapies.
